Search Results

A recent study found that Aetrex Premium Memory Foam Orthotics, both with and without metatarsal support, are clinically proven to reduce common sources of pain (i.e., back, foot, hip, knee and ankle pain) and the fear of falling for seniors. A recent study found that Aetrex Premium Memory Foam Orthotics, both with and without metatarsal support, are clinically proven to reduce common sources of pain (i.e., back, foot, hip, knee and ankle pain) and the fear of falling for seniors.

Enzolytics, Inc. (OTC PINK:ENZC) (“enzolytics.com”) (the “Company”) announced today that the Company is entering into a worldwide exclusive licensing agreement for US Patent # 8067531-B2, “Inactivated pepsin fragments for modulating immune system activity against human malignant tumor cells,” applying Immunotherapy Treatment to the global fight against cancer.

Kane Biotech Inc. announces that it has entered into a worldwide license agreement with I-MED Pharma Inc. (“I-MED Pharma” or “I-MED”) for the DispersinB ® technology.

Shionogi & Co., Ltd. and Maze Therapeutics, Inc. announced the companies have completed an exclusive worldwide license agreement for the rights to MZE001, an investigational oral glycogen synthase 1 inhibitor that aims to address Pompe disease by limiting disease-causing glycogen buildup.

Autonomix Medical, Inc. announced that it has regained exclusive worldwide rights to its technology for cardiology field use from Impulse Medical, Inc.

Xeris Biopharma Holdings, Inc. announced that it has entered into an exclusive worldwide collaboration and license agreement with Beta Bionics, Inc. for the development and commercialization of a glucagon product utilizing Xeris’ XeriSol™ technology for use in Beta Bionics’ proprietary bi-hormonal pump and pump systems.

Takeda and Protagonist Therapeutics, Inc., announced the signing of a worldwide license and collaboration agreement for the development and commercialization of rusfertide, an investigational injectable hepcidin mimetic peptide of the natural hormone hepcidin, currently in a pivotal Phase 3 trial, VERIFY, for the treatment of Polycythemia Vera.

AbelZeta Pharma, Inc. announced an amendment of its worldwide collaboration and license agreement with Janssen Biotech, Inc., a Johnson & Johnson company.

EA Pharma Co., Ltd. and Ensho Therapeutics, Inc. announced that the two companies have signed a worldwide exclusive license agreement for the rights to develop, manufacture and commercialize novel oral inflammatory bowel disease treatments EA1080 and a portfolio of other oral selective α4β7 integrin antagonists for the global market excluding Japan, China, Hong Kong, Macau, South Korea, Taiwan and ASEAN.